Two replicate , double-blind , randomized , @-week studies ( ANHELTO @ -LSB- NCT@ -RSB- and ANHELTO @ -LSB- NCT@ -RSB- ) evaluated the efficacy and safety of olodaterol @ g once daily ( via Respimat ( ) ) combined with tiotropium @ g once daily ( via HandiHaler ( ) ) versus tiotropium @ g once daily ( via HandiHaler ( ) ) combined with placebo ( via Respimat ( ) ) in patients with moderate to severe COPD .